Latest Breaking News On - Innovatus life sciences lending fund - Page 2 : vimarsana.com

APOLLO ENDOSURGERY, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, (form 8-K)

Item 1.02 Termination of a Material Definitive Agreement. On April 4, 2023, in connection with the consummation of the Merger, the Company paid in full all outstanding obligations under, and. | April 4, 2023

Celcuity Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Celcuity Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Celcuity Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Celcuity Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update

Celcuity Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update ACCESSWIRE 11 May 2021, 06:05 GMT+10 Entered into worldwide licensing agreement with Pfizer to develop and commercialize gedatolisib, a first-in-class PI3K/mTOR inhibitor, in clinical development for breast cancer Announced encouraging preliminary data from a Phase 1b trial of gedatolisib plus Ibrance® and endocrine therapy for patients with ER+/HER2- metastatic breast cancer, in which gedatolisib showed a potentially differentiated safety and tolerability profile Secured additional financing to strengthen cash position and provide funding for expanded clinical development activities Entered into clinical trial collaboration agreements with leading cancer research centers, Novartis, Pfizer, and Puma to evaluate the efficacy of targeted therapies in patients selected with Celcuity s CELsignia Multi-Pathway Activity Test